posted by admin in Uncategorized
Since the public became aware of the disease HIV/Aids in the 1980’s one of the challenges the medical community and those suffering from it has had was to develop drugs to fight the disease. People infected with the HIV virus have to take an extensive cocktail of drugs just to stay alive and these drugs are expensive. In some cases HIV infected person were taking up to four different drugs a couple of times per day. This regiment is about to change.

In August this year, the Food and Drug Administration in the United States approved a daily HIV pill developed by Gilead Sciences.
The new once-daily HIV pill, Complera, is comprised of two types of HIV drugs, and is a combination of two individual HIV drugs currently on the market: Edurant, developed by Johnson & Johnson, and Truvada, developed by Gilead.
Complera, which is estimated to cost $1,705 a month, requires a prescription and is intended exclusively for patients with no prior HIV treatment. Persons with HIV are now rejoicing somewhat as they can have more control over their lives. They are able to enjoy ball games, watch movies they saved using a R4i Card on their new Nintendo 3DS system, or even to do work.
Complera is not Gilead’s only once-daily HIV pill. The company also makes Atripla, which is a combination of Truvada and Sustiva, developed by Bristol-Myers Squibb. Altripla will lose patent protection within the next few years. The looming loss of revenue has put pressure on the company to bring new drugs to market faster.
In January 2011, the FDA rejected Gilead’s application for Complera, stating there was insufficient information in the application. In September 2010, the company received a FDA warning letter regarding potential manufacturing problems and quality control at Gilead’s San Dimas plant in California.
Along with Complera’s approval, the company also announced it had resolved the issues and concerns cited in the September FDA letter. After news of both developments was received, Gilead’s stock rose nearly three percent.
similar posts:
Tories Stories : Well we all wanted this glorious, amazingly…
Truth Hurts : And while many people tend to believe that N…
Tips for buying cheap flights : …
A Pipedream? : Not long ago, most people would have chosen the…